Market Overview

Is The FDA Panel Vote On Puma Biotech Likely To Lead To Actual Approval?

Share:
Is The FDA Panel Vote On Puma Biotech Likely To Lead To Actual Approval?
Related
Benzinga's Top Upgrades, Downgrades For September 17, 2018
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) hit a new 52-week high of $80.00 Thursday morning after the company confirmed that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12–4 to recommend approval of PB272 (neratinib) for the treatment of early stage breast cancer.

12–4, But No Definitive Approval ... Yet

Following the vote, Credit Suisse's Alethia Young maintained an Outperform rating on Puma's stock with a price target boosted from $58 to $90, although the company's announcement doesn't yet imply the approval of neratinib. The analyst did state that the FDA's vote of 12–4 in favor of approval now increases the odds of ultimate approval from 75 percent to 100 percent.

According to Young, the key debate among the panel surrounded what is the right subset of patients that see benefits from neratinib and limiting eligibility of neratinib use for patients that had completed adjuvant treatment less than two years with Herceptin.

"We only model use in HR+ patients, so even if the label is limited to that subgroup we don't see significant downside from that," Young explained. "We would be cautious to assume that there was a healthy debate around the trial amendments and statistics, but overall it seemed that the concerns were manageable."

Finally, the analyst suggested that the next major catalyst for Puma's stock is the full data presentation Roche's APHINITY study, which "looks at extended adjuvant use of Herceptin and Perjeta for a year."

At time of publication, shares of Puma Bio were up 3.4 percent at $77.50.

Related Links:

Benzinga's Top Upgrades, Downgrades For May 25, 2017

The Next Steps For OncoCyte After Better-Than-Expected Data

Latest Ratings for PBYI

DateFirmActionFromTo
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018CitigroupMaintainsBuyBuy
Sep 2018Goldman SachsInitiates Coverage OnSell

View More Analyst Ratings for PBYI
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration FDA Events Best of Benzinga

 

Related Articles (PBYI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

An Ellen Special Is Coming To Netflix + 3 Other Hotly-Anticipated Titles For 2017

Taking A Look At What Acquiring Kate Will Really Mean For Coach